206 438

Cited 0 times in

Prediction for TNF Inhibitor Users in RA Patients According to Reimbursement Criteria Based on DAS28

Other Title
류마티스관절염에서 DAS28에 근거한 보험급여기준 적용시 항 TNF제제 대상 환자 예측
Authors
원, 소영; 성, 윤경; 조, 수경; 최, 찬범; 고, 은미; 김, 성규; 김, 진석; 김, 태환; 김, 현아; 나, 성수; 방, 소영; 서, 창희; 심, 승철; 유, 대현; 윤, 보영; 이, 상훈; 이, 성원; 이, 신석; 이, 연아; 이, 재준; 이, 지수; 이, 혜순; 임, 미경; 전, 재범; 전, 찬홍; 정, 영옥; 정, 원태; 차, 훈석; 최, 정윤; 홍, 승재; 배, 상철
Citation
Journal of rheumatic diseases, 21(2):64-73, 2014
Journal Title
Journal of rheumatic diseases; 대한류마티스학회지
ISSN
2093-940X2233-4718
Abstract
Objective: The purpose of this study is to examine the dif-ference between the numbers of patients in rheumatoid ar-thritis (RA) who are eligible to TNF inhibitors by the past Korean National Health Insurance reimbursement guide-line and by the disease activity score with 28-joint assess-ment (DAS28) based criteria.



Methods: Data were obtained from a multi-center registry for biologics users in Korean RA patients, BIOlogics Phar-macoepidemiologic StudY (BIOPSY). DAS28 was calcu-lated based on either ESR or CRP, and DAS28 of more than 5.1 or between 3.2 and 5.1 with radiographic changes was defined as a cut-off point for the initiation of TNF inhibitors. For the maintenance criteria, we used both of improving in DAS28 score (>1.2) and low disease activity (DAS 28<3.2). Differences between the numbers in each step by two criteria were described with Chi-square test and Kappa agreement.



Results: Of the 489 patients in BIOPSY, 299 were included in this study. Among them, 278 patients (93.0%) were eli-gible of TNF inhibitors when we applied the new initiation criteria with DAS28-ESR, and 244 patients (81.6%) were indicated for TNF inhibitors with DAS28-CRP. For the maintenance criteria, a low disease activity (DAS28<3.2) in 3 months after starting TNF inhibitors is too strict for achieving (33.6% with DAS28-ESR and 50.0% with DAS28-CRP). Instead, decreasing DAS28 by more than 1.2 is moe reasonable as a tool for deciding early responsive-ness of TNF inhibitors in RA patients (81.2% both with DAS28-ESR and DAS28-CRP).



Conclusion: Our results show that the candidates for TNF inhibitors will be enormously changed according to a change in the reimbursement criteria. To define appro-priate patients to receive TNF inhibitors, a further study with regard to the impact of changes in the reimbursement criteria on the outcomes of RA patients will be required.
Keywords
Korean National Health Insurance reimburse-ment criteriaRheumatoid arthritisTNF inhibitorDAS28
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Rheumatology
AJOU Authors
김, 현아서, 창희
Files in This Item:
64-73.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse